In vivo CAR Engineering

Empowering the Next Generation of Cell Therapy with VHH Nanobody Solutions

  • VHHs (Nanobodies) are compact, ultra-stable antigen-binding domains that offer superior tissue penetration and modularity for complex therapeutic designs.VHHs can serve as both high-affinity CAR constructs and precision targeting heads to reprogram T cells in invivo CAR engineering.
  • We leverage cell-based screening to ensure VHHs recognize target proteins in their native conformation with pM-level binding potency. Our antibodies are rigorously validated for high specificity with negligible non-specific binding, ensuring a superior safety profile for clinical translation.

Precision CAR-Monitoring

High-Sensitive Anti-ID Ab for PK/PD and ADA Assessment

  • CytoArt is the first commercial producer of anti-idiotype antibody for CAR-T detection. We cover 6 FDA-approved CAR-T targets worldwide.
  • Our product portfolio enables robust CAR molecule tracking (PK/PD) and highly sensitive detection of anti-drug antibodies (ADA) across diverse technology platforms, including Flow Cytometry, ELISA and MSD.
  • Data Integrity – Provide reproducible, regulatory-grade evidence to support clinical decision-making.

Our Technology Platform Excellence

Specialized Antibody Solutions with Guaranteed Quality

CytoArt boasts years of technical expertise with extensive experience in antibody discovery and production. Powered by a proprietary platform, a specialized team, and over 8 years of focus on anti-idiotypic antibodies, we enable rapid generation of high-quality antibodies (including VHHs)—delivering monoclonal antibodies in as few as 20 weeks.

Solutions for NHP Models

Rapid Assay Optimization & Technical Troubleshooting

Leu16-scFv anti-CD20 CAR, effective in both human and non-human primate (NHP) models, has become a widely adopted model for evaluating in vivo CAR-T delivery and function in preclinical animal studies.

To address the challenge of non-specific binding in monkey blood, we have optimized our antibody to significantly reduce background noise and ensure reliable assay results.

Latest News

CytoArt to Exhibit at TRCCC Annual Meeting | Connect with Our Team for CAR-T Solutions

CytoArt will participate in the TRCCC (Translational Research Cancer Centers Consortium) conference, with team members Dee LaVigne and Stephen Haley stationed at our on-site booth.

CytoArt Attends SITC Spring Scientific Conference Hosted in Tucson

CytoArt Co-Founder Frank Li participated in the SITC Spring Scientific Conference, which was locally held in Tucson, Arizona.

CytoArt’s Anti-Idiotype & VHH Solutions to Be Showcased at AACR 2026 (Booth #803)

CytoArt’s core team travels from Tucson headquarters to San Diego for the AACR 2026 Annual Meeting, taking residence at Booth #803 during April 17–22.

Customer Reviews

“We have stained the samples with your reagents. It works very well and will purchase this reagents once we need in our future study. Thank you very much for your support and wonderful reagent.”
 

——Y***O

“Both abs worked great and no significant difference between the two clones. We already have our CRO purchase and use your ab in the official run.”

 

——F***N

“I would like to use the CytoArt anti FMC63 PE antibody for flowcytometry as is cleaner than our usual antibody.”

——L***O

Cytoart
in vivo CAR
CAR Monitor
Technology
Case Study
News
Reviews